Funding for this research was provided by:
MEXT | Japan Society for the Promotion of Science (21H02846)
National Natural Science Foundation of China (81772044)
Article History
Received: 21 March 2023
Revised: 18 July 2023
Accepted: 19 July 2023
First Online: 25 July 2023
Competing interests
: KH is the inventor of filed patent applications on “The use of <i>R</i>-Ketamine in the treatment of psychiatric diseases”, “(<i>S</i>)-norketamine and salt thereof as pharmaceutical”, “<i>R</i>-Ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition function disorder”, “Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases”, and “<i>R</i>-Ketamine and its derivatives as a preventive or therapeutic agent for a neurodevelopmental disorder” by the Chiba University. KH has also received speakers’ honoraria, consultant fees, or research support from Abbott, Boehringer-Ingelheim, Daiichi-Sankyo, Meiji Seika Pharma, Seikagaku Corporation, Dainippon-Sumitomo, Taisho, Otsuka, Murakami Farm and Perception Neuroscience. The other authors declare no competing interests.